UTD-Ind
JCO-ovid
Indian Journal of Cancer
Home  ICS  Feedback Subscribe Top cited articles Login 
Users Online :961
Small font sizeDefault font sizeIncrease font size
Resource Links
     Search Pubmed for
 
    -  Deb U
    -  Mukhopadhyay S
    -  Banerjee S
    -  Biswas S
 

 Article Access Statistics
    Viewed299    
    PDF Downloaded10    

Recommend this journal

 

 ORIGINAL ARTICLE

Safety profile of G-CSF in chemotherapy-induced neutropenia: A prospective observational study in Eastern India


1 Department of Pharmacology, Burdwan Medical College, Burdwan, West Bengal, India
2 Department of Radiotherapy, Burdwan Medical College, Burdwan, West Bengal, India

Correspondence Address:
Uttiya Deb,
Department of Pharmacology, Burdwan Medical College, Burdwan, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijc.IJC_982_19

PMID: 33753622

Background: Granulocyte-colony stimulating factor (G-CSF) is used in cancer patients to treat chemotherapy-induced neutropenia (CIN). However, G-CSF poses few risks. Despite the regular use of G-CSF in CIN management, there is a paucity of published data on its safety profile in the management of CIN in India. Hence, the present study was designed to demonstrate the safety profile of G-CSF in patients with CIN. Methods: A prospective observational study was conducted over a period of 5 months enrolling 100 cancer patients aged from 18 years to 70 years. Patients with a diagnosis of CIN who received G-CSF were included. Patients were followed up for 15 days. Adverse events (AEs) were graded according to US National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The system organ class and preferred term of Medical Dictionary for Regulatory Activities (MedDRA) were used for reporting the AEs. Causality assessment was done by using the WHO-Uppsala Monitoring Centre scale. Results: The most frequently reported AEs were musculoskeletal and connective tissue disorders which included bone pain, myalgia, arthralgia, and pain in the extremity. Other AEs reported were general disorders and administration site conditions, and gastrointestinal disorders. The highest grade of toxicity reported was of grade 3 among all AEs. The majority of AEs had a “probable” type of causality relationship with G-CSF. Conclusion: G-CSF has a safety profile consistent with previous G-CSF studies. Criteria for Adverse Events, filgrastim, granulocyte-colony stimulating factor, Medical Dictionary for Regulatory Activities




  Site Map | What's new | Copyright and Disclaimer
  Online since 1st April '07
  2007 - Indian Journal of Cancer | Published by Wolters Kluwer - Medknow